Kou-Rong Miao

Kou-Rong Miao

Auto-generated profile, based on publicly available information

Kou-Rong Miao

Department of Hematology the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
GYGuangli Yin
Guangli Yin
ZXZhengrui Xiao
Zhengrui Xiao
YNYing Ni
Ying Ni
XQXiaoyan Qu
Xiaoyan Qu
HWHanxin Wu
Hanxin Wu
KMKourong Miao
Kourong Miao

1 June 2011 in Leukemia Research
Verified
Journal Article
Closed access
DZDan-Xia Zhu
Dan-Xia Zhu
KMKou-Rong Miao
Kou-Rong Miao
CFCheng Fang
Cheng Fang
LFLei Fan
Lei Fan
WZWei Zhu
Wei Zhu
JLJian-Yong Li
Jian-Yong Li

1 January 2015 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
JSJinning Shi
Jinning Shi
YNYing NI
Ying NI
JLJianyong Li
Jianyong Li
HQHairong Qiu
Hairong Qiu
KMKourong Miao
Kourong Miao
The current study presents the case of a 78‑year‑old male with concurrent chronic neutrophilic leukemia (CNL) and multiple myeloma (MM) who developed acute myeloid leukemia after two years of treatment with hydroxyurea, cyclophosphamide, prednisone and thalidomide. The patient presented with mature neutrophilic leukocytosis, hepatosplenomegaly, a high neutrophil alkaline phosphatase score and an absence of the Philadelphia chromosome or the BCR‑ABL fusion gene. A bone marrow aspirate smear and biopsy indicated that the CNL coexisted with a plasma cell neoplasm. In addition, monoclonal λ‑paraproteinemia was detected by serum protein immunofixation electrophoresis, and bone lesions were identified in multiple vertebrae. The patient achieved complete remission following one cycle of induction chemotherapy with the decitabine regimen in combination with the low‑dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (CAG) priming regimen. The occurrence of CNL and MM concurrently is extremely rare and thus, it has only been reported in a small number of cases. The occurrence of CNL and MM in the same patient as two distinct hematological malignancies indicates the neoplastic transformation of a pluripotent stem cell. Decitabine combined with the CAG priming regimen may present a good therapeutic strategy for elderly patients with secondary acute myeloid leukemia.

4 April 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
HDHua-Jie Dong
Hua-Jie Dong
KMKou-Rong Miao
Kou-Rong Miao
CQChun Qiao
Chun Qiao
YZYun Zhuang
Yun Zhuang
WSWen-Yi Shen
Wen-Yi Shen
JLJian-Yong Li
Jian-Yong Li
The human multidrug resistance (MDR1, ABCB1) gene encodes P-glycoprotein (P-gp), which affects the pharmacokinetics of many drugs. Here, we investigated whether common MDR1 single nucleotide polymorphisms (SNPs) (C1236T, C3435T, and G2677T/A) affect predisposition to chronic lymphocytic leukemia (CLL). Genotyping was performed in 150 patients with CLL and 117 controls using polymerase chain reaction (PCR)-based assays. Haplotypes were inferred using the PHASE algorithm. We found comparable allele and genotype frequencies among patients with CLL and controls. Moreover, patient and control groups did not differ regarding MDR1 haplotype distribution (p = 0.97). Furthermore, no correlation was shown between the MDR1 1236, 3435, or 2677 genotypes and Binet stage, unmutated immunoglobulin heavy-chain variable region (IGHV) status, CD38 expression, ZAP-70 expression, and p53 deletion. In conclusion, our results do not support a major influence of MDR1 variants on the risk of CLL, and these genomic polymorphisms are not associated with clinical prognostic factors in Chinese patients with CLL.

1 July 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
YNYing Ni
Ying Ni
ZXZhengrui Xiao
Zhengrui Xiao
GYGuangli Yin
Guangli Yin
LFLei Fan
Lei Fan
LWLi Wang
Li Wang
KMKourong Miao
Kourong Miao

17 October 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
ZDZiwen Duan
Ziwen Duan
XZXiao Zhang
Xiao Zhang
YLYanping Liu
Yanping Liu
FLFang Li
Fang Li
HSHaorui Shen
Haorui Shen
KMKourong Miao
Kourong Miao
Refractory cytomegalovirus reactivation (RCR) after allo-hematopoietic stem cell transplantation (HSCT) is associated with poor outcomes. Current studies for the risk factors and survival of patients with post-transplantation RCR remain limited. 163 patients with Cytomegalovirus (CMV) reactivation undergoing allo-HSCT in Jiangsu Province hospital from Jan 2013 to Dec 2020 were analyzed retrospectively. Multivariate analysis revealed that highest CMV viremia>1 × 104copies/mL (hazard ratio [HR] 16.895, 95% confidence interval [CI] 3.394-84.109, P = 0.001) and platelet count at Day 90 of more than 87.3 × 109/L (HR 0.381, 95% CI 0.154-0.945, P = 0.037) were independent risk factors affecting RCR. As for prognosis of patients with CMV reactivation, results showed that patients with RCR had higher risk of non-relapse mortality (NRM) (39.5% vs. 22.5%, P = 0.045), and RCR was an independent risk factor for NRM (HR 2.216, 95% CI 1.137-4.317, P = 0.019). There was no significance between patients with or without RCR in terms of overall survival (OS) (50.7% vs. 55.6%, P = 0.281) and relapse-free survival (RFS) (43.6% vs. 52.0%, P = 0.179). The landmark analysis showed that patients with RCR had higher NRM (P = 0.01), worse OS (P = 0.02), and RFS (P =0.01) within 100 days after transplantation. Patients with hemorrhagic cystitis (40.9% vs. 64.5%, P =0.028) and who developed viremia>1 × 105copies/mL (43.4% vs. 58.4%, P = 0.033) were associated with worse OS. Factors such as higher viral load, thrombocytopenia, and ATG used in conditioning therapy increased the incidence of RCR. Patients with RCR had worse NRM, OS, and RFS within 100 days after transplantation.